Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-15
2005-11-15
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S475000
Reexamination Certificate
active
06964981
ABSTRACT:
The present invention relates compounds that are NK-1 antagonists and that are of use in the treatment or prevention of depression, anxiety, pain, inflammation, migaine, emesis or postherpetic neuralgia.
REFERENCES:
patent: 5750549 (1998-05-01), Caldwell et al.
Honoo Satake et al, Zoological Science, 20: 533-549, 2003.
Reichard, G. A. Et Al: “The design and synthesis of novel NK1/NK2 dual antagonists”, Bioorganic & Medicinal Chemistry Letters, vol. 10, No. 20, Oct. 16, 2000, pp. 2329-2332.
Owen Simon Neil
Swain Christopher John
Williams Brian John
Merck Sharp & Dohme Ltd.
Saeed Kamal A.
Thies J. Eric
Winokur Melvin
LandOfFree
Tetrahydrofuran derivatives and their use as NK-1 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydrofuran derivatives and their use as NK-1 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydrofuran derivatives and their use as NK-1 antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3455986